CD27 Fc Chimera Protein, Mouse,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Mouse
Synonyms	TNFRSF7, T14, S152, Tp55, Cluster of differentiation 27
Accession	P41272
Amino Acid Sequence	Thr21-Arg182 with Human IgG1 Fc at the C-Terminus
Expression System	HEK293
Molecular Weight	50-70kDa (Reducing)
Purity	>95% by SDS-PAGE, RP-HPLC&SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	Human IgG1 Fc
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, pH7.4, 5% trehalose
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	Drner T. et al. (2004) Correlation of circulating CD27 high plasma cells and disease activity in systemic lupus erythematosus. Lupus. 13(5): 283-289. Sahota S S. et al. (2009) CD27 in defining memory B-cell origins in Waldenstrm's macroglobulinemia. Clin Lymphoma Myeloma. 9(1): 33-35. Jiang J. et al. (2010) Reduced CD27 expression on antigen-specific CD4+ T cells correlates with persistent active tuberculosis. J Clin Immunol. 30(4): 566-573.

Background

Cluster of Differentiation 27 (CD27) is a member of the Tumor Necrosis Factor Receptor superfamily and is integral to T-cell activation, providing a crucial costimulatory signal. When CD27 binds to its natural ligand, CD70, it enhances T-cell proliferation and the differentiation of effector and memory T cells. This interaction holds potential as an immune modulatory target for cancer treatment.
The CD27 agonistic antibody, varlilumab, has demonstrated promising efficacy in both hematological malignancies and solid tumors. Current research is focused on studying the combination therapy of varlilumab with PD-1 axis inhibitors, such as nivolumab or atezolizumab, which target immune checkpoint pathways.
Furthermore, CD70 expression is being explored as a therapeutic target for Antibody-Drug Conjugates (ADCs), antibodies that induce Antibody-Dependent Cellular Cytotoxicity (ADCC), as well as for chimeric antigen receptor (CAR) gene-modified T cells and specific dendritic cell vaccinations.
Clinical trials have shown that targeting the CD27 axis is feasible and safe, with the most common side effects being thrombocytopenia, fatigue, and nausea.